

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository:<https://orca.cardiff.ac.uk/id/eprint/137855/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Vanden Avond, Mark A., Meng, Hui, Beatka, Margaret J., Helbling, Daniel C., Prom, Mariah J., Sutton, Jessica L., Slick, Rebecca A., Dimmock, David P., Pertusati, Fabrizio, Serpi, Michaela, Pileggi, Elisa, Crutcher, Patrick, Thomas, Stephen and Lawlor, Michael W. 2021. The nucleotide prodrug CERC-913 improves mtDNA content in primary hepatocytes from DGUOK-deficient rats. *Journal of Inherited Metabolic Disease* 44 (2), pp. 492-501. 10.1002/jimd.12354

Publishers page: <http://dx.doi.org/10.1002/jimd.12354>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



# Journal of Inherited Metabolic Disease

## The Nucleotide Prodrug CERC-913 Improves mtDNA Content in Primary Hepatocytes from DGUOK-Deficient Rats --Manuscript Draft--

Manuscript Number:	BOLI-D-19-00306R1	
Full Title:	The Nucleotide Prodrug CERC-913 Improves mtDNA Content in Primary Hepatocytes from DGUOK-Deficient Rats	
Article Type:	Original Article	
Keywords:	mtDNA depletion syndrome, primary hepatocyte cell culture, ProTide, deoxyguanosine kinase, deoxyguanosine kinase deficiency	
Manuscript Classifications:	170: Mitochondrial disorders: mtDNA	
Corresponding Author:	Michael Lawlor Medical College of Wisconsin Milwaukee, UNITED STATES	
Corresponding Author Secondary Information:		
Corresponding Author's Institution:	Medical College of Wisconsin	
Corresponding Author's Secondary Institution:		
First Author:	Mark Vanden Avond	
First Author Secondary Information:		
Order of Authors:	Mark Vanden Avond	
	Hui Meng	
	Margaret Beatka	
	Daniel C Helbling	
	Mariah J Prom	
	Jessica L Sutton	
	Rebecca A Slick	
	David Dimmock	
	Fabrizio Pertusati	
	Michaela Serpi	
	Elisa Pileggi	
	Patrick Crutcher	
	Stephen Thomas	
	Michael W. Lawlor	
Order of Authors Secondary Information:		
Funding Information:	Ichorion Therapeutics (N/A)	Dr. Michael W. Lawlor
Abstract:	Loss-of-function mutations in the deoxyguanosine kinase (DGUOK) gene result in a mitochondrial DNA (mtDNA) depletion syndrome. DGUOK plays an important role in converting deoxyribonucleosides to deoxyribonucleoside monophosphates via the salvage pathway for mtDNA synthesis. DGUOK deficiency manifests predominantly in the liver; the most common cause of death is liver failure within the first year of life and no therapeutic options are currently available. In vitro supplementation with deoxyguanosine or deoxyguanosine monophosphate (dGMP) were reported to rescue	

mtDNA depletion in DGUOK-deficient, patient-derived fibroblasts and myoblasts. CERC-913, a novel ProTide prodrug of dGMP, was designed to bypass defective DGUOK while improving permeability and stability relative to nucleoside monophosphates. To evaluate CERC-913 for its ability to rescue mtDNA depletion, we developed a primary hepatocyte culture model using liver tissue from DGUOK-deficient rats. DGUOK knockout rat hepatocyte cultures exhibit severely reduced mtDNA copy number (~10%) relative to wild type by qPCR and mtDNA content remains stable for up to eight days in culture. CERC-913 increased mtDNA content in DGUOK-deficient hepatocytes up to 2.4-fold after 4 days of treatment in a dose-dependent fashion, which was significantly more effective than dGMP at similar concentrations. These early results suggest primary hepatocyte culture is a useful model for the study of mtDNA depletion syndromes and that CERC-913 treatment can improve several disease-associated phenotypes in this model.

[Click here to access/download;Manuscript;CERC-913 cerecor paper revision for submission 10-30-2020.docx](#)

1  
2  
3  
4 **The Nucleotide Prodrug CERC-913 Improves mtDNA Content in Primary Hepatocytes**  
5  
6 **from DGUOK-Deficient Rats**  
7

8  
9  
10  
11 Mark Vanden Avond<sup>1\*</sup>, Hui Meng<sup>1\*</sup>, Margaret Beatka<sup>1</sup>, Daniel C Helbling<sup>1</sup>, Mariah Prom<sup>1</sup>,  
12 Jessica L Sutton<sup>1</sup>, Rebecca A Slick<sup>1</sup>, David Dimmock<sup>2</sup>, Fabrizio Pertusati<sup>3</sup>, Michaela Serpi<sup>3</sup>,  
13 Elisa Pileggi<sup>3</sup>, Patrick Crutcher<sup>4</sup>, Stephen Thomas<sup>4</sup>, Michael W. Lawlor<sup>1</sup>  
14  
15  
16  
17  
18  
19  
20  
21

22 <sup>1</sup> Department of Pathology and Laboratory Medicine and Neuroscience Research Center,  
23 Medical College of Wisconsin, Milwaukee, WI, USA  
24

25  
26 <sup>2</sup> Rady Children's Institute for Genomic Medicine, Rady Children's Hospital, San Diego, CA,  
27 USA  
28

29  
30  
31 <sup>3</sup> School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK  
32

33 <sup>4</sup> Discovery R&D, Cerecor Inc., Rockville, MD, USA  
34  
35  
36

37 **Keywords:** mtDNA depletion syndrome, primary hepatocyte cell culture, ProTide,  
38 deoxyguanosine kinase, deoxyguanosine kinase deficiency  
39  
40  
41  
42  
43

44 **Word Count: 3434**

45  
46 **Number of Tables: 0**

47  
48  
49 **Number of Figures: 4**  
50

1  
2  
3 51  
52  
53  
54  
55  
56  
57  
58  
59  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54

**Support:** This work was supported through a Sponsored Research Agreement from Ichorion Therapeutics, which has since been acquired by Cerecor. The corresponding author confirms independence from the sponsor.

**Acknowledgements:** We would like to thank Dr. Aniko Szabo of the Biostatistics Consulting Center at the Medical College of Wisconsin for her helpful advice on statistical evaluation.

**Corresponding Author:** Mail; Michael W. Lawlor, MD, PhD, 8701 Watertown Plank Road, TBRC Building, Room C4490, Milwaukee, WI 53226; E-mail; [mlawlor@mcw.edu](mailto:mlawlor@mcw.edu)

**Compliance with Ethics Guidelines:**

Conflicts of Interest:

Dr. Lawlor is or was recently a member of advisory boards for Audentes Therapeutics, Ichorion Therapeutics, and Solid Biosciences and receives or has recently received research support from these companies. Dr. Lawlor is also a consultant for Audentes Therapeutics, Encoded Therapeutics, AGADA Biosciences, Prothelia, Biomarin,, Kate Therapeutics, Lacerta Therapeutics, Affinia Therapeutics, Modis Therapeutics, Rocket Therapeutics, and Dynacure.

Dr. Thomas is a recent employee of Ichorion Therapeutics and Cerecor.

Mr. Crutcher are recent employees of Ichorion Therapeutics and Cerecor.

Dr. Dimmock was recently a member of the scientific advisory board for Audentes Therapeutics and a consultant for Biomarin.

Dr. Pertusati was a member of scientific advisory board for Ichorion therapeutics.

Mark Vanden Avond has no conflict of interest.

Hui Meng has no conflict of interest.

Margaret Beatka has no conflict of interest.

Daniel Helbling has no conflict of interest.

Mariah Prom has no conflict of interest.

1  
2  
53  
56  
57  
58  
59  
60

Jessica Sutton has no conflict of interest.

Rebecca Slick has no conflict of interest.

Michaela Serpi has no conflict of interest.

1  
2  
3  
4 Elisa Pileggi has no conflict of interest.  
5  
6  
7

8  
9 Informed Consent: This project did not involve human studies.  
10

11 Animal Rights: All institutional and national guidelines for the care and use of laboratory animals  
12 were followed. IACUC Protocol: Medical College of Wisconsin AUA00005428  
13  
14

15  
16 Justification of Authorship:  
17

18 Vanden Avond\*: Data acquisition and interpretation, figure design, and drafting of the  
19 manuscript  
20

21  
22 Meng\*: Data acquisition and interpretation, figure design, and drafting of the manuscript  
23

24 Beatka: Data acquisition, interpretation, and figure design and review of the manuscript  
25

26 Helbling: Data acquisition and interpretation and review of the manuscript  
27

28 Prom: Data acquisition and interpretation, and figure design and review of the manuscript  
29

30 Sutton: Data acquisition and interpretation and review of the manuscript  
31

32 Slick: Data acquisition and interpretation and review of the manuscript  
33

34 Dimmock: Data interpretation, and drafting of the manuscript  
35

36 Pertusati: Data acquisition and interpretation, and figure design and review of the manuscript  
37

38 Serpi: Data acquisition and interpretation, and figure design and review of the manuscript  
39

40 Pileggi: Data acquisition and interpretation, and figure design and review of the manuscript  
41

42 Crutcher: Data acquisition and interpretation, figure design, and drafting of the manuscript  
43

44 Thomas: Data acquisition and interpretation, figure design, and drafting of the manuscript  
45

46 Lawlor: Data acquisition and interpretation, figure design, and drafting of the manuscript  
47  
48  
49

50  
51  
52  
53  
54 \*Please note that we are requesting co-first authorship for authors vanden Avond and Meng as  
55 they both did extensive proportions of the work at all levels.  
56  
57  
58

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Abstract**  
5

6 Loss-of-function mutations in the deoxyguanosine kinase (DGUOK) gene result in a  
7 mitochondrial DNA (mtDNA) depletion syndrome. DGUOK plays an important role in converting  
8 deoxyribonucleosides to deoxyribonucleoside monophosphates via the salvage pathway for  
9 mtDNA synthesis. DGUOK deficiency manifests predominantly in the liver; the most common  
10 cause of death is liver failure within the first year of life and no therapeutic options are currently  
11 available. *In vitro* supplementation with deoxyguanosine or deoxyguanosine monophosphate  
12 (dGMP) were reported to rescue mtDNA depletion in DGUOK-deficient, patient-derived  
13 fibroblasts and myoblasts. CERC-913, a novel ProTide prodrug of dGMP, was designed to  
14 bypass defective DGUOK while improving permeability and stability relative to nucleoside  
15 monophosphates. To evaluate CERC-913 for its ability to rescue mtDNA depletion, we  
16 developed a primary hepatocyte culture model using liver tissue from DGUOK-deficient rats.  
17 DGUOK knockout rat hepatocyte cultures exhibit severely reduced mtDNA copy number (~10%)  
18 relative to wild type by qPCR and mtDNA content remains stable for up to eight days in culture.  
19 CERC-913 increased mtDNA content in DGUOK-deficient hepatocytes up to 2.4-fold after 4  
20 days of treatment in a dose-dependent fashion, which was significantly more effective than  
21 dGMP at similar concentrations. These early results suggest primary hepatocyte culture is a  
22 useful model for the study of mtDNA depletion syndromes and that CERC-913 treatment can  
23 improve several disease-associated phenotypes in this model.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 **Synopsis**  
51

52  
53 Treatment of a DGUOK KO rat primary hepatocyte model of mitochondrial DNA (mtDNA)  
54 depletion model was with CERC-913 allowed mtDNA recovery exceeding that observed with  
55 dGMP treatment.  
56  
57  
58

59  
60  
61  
62  
63  
64  
65



## Introduction

Mitochondrial DNA (mtDNA) depletion syndrome (MDS) is a group of rare autosomal-recessive diseases characterized by reduction of mitochondrial DNA copy number in specific tissues.

Genetic causes of MDS are heterogeneous and are principally involved in mtDNA maintenance and replication.

*DGUOK* mutations account for 14% of MDS cases (Salviati et al 2002), which constitutes the most common genetic abnormality associated with hepatic mitochondrial DNA depletion syndromes (Sezer et al 2015). Patients with *DGUOK* deficiency typically present with liver dysfunction at birth, with or without neurological impairment, and most die within the first year of life due to liver failure. *DGUOK* is a nuclear gene which encodes mitochondrial deoxyguanosine kinase (DGUOK). DGUOK plays an important role in mtDNA synthesis by phosphorylating purine deoxyribonucleosides to produce deoxyadenosine monophosphate (dAMP) and deoxyguanosine monophosphate (dGMP) (Gower et al 1979).

The pathogenesis of *DGUOK* deficiency has been studied using patient-derived cell cultures and rodent models, which have provided insights into tissue-specific manifestations of the disease. While mtDNA synthesis can occur during S phase via cytosolic supply of deoxynucleoside triphosphates (dNTPs) irrespective of *DGUOK*, mutation of *DGUOK* compromises cell cycle independent mtDNA synthesis (Taanman et al 2003). This has little impact on mtDNA content in tissues undergoing active replication but leads to drastically reduced mtDNA in quiescent tissues, including liver, muscle and brain, since cytosolic dNTP supply is down-regulated. Studies using *DGUOK*-mutant cell cultures established that treatment of cells with deoxyguanosine and deoxyadenosine, or with dGMP and dAMP, was

capable of partially correcting mtDNA content (Taanman et al 2003; Saada 2008; Bulst et al

1  
2  
3  
4 2009; Bulst et al 2012). While Munro et al (2019) showed a recovery in liver mtDNA content  
5  
6 when supplemented with deoxyguanosine + deoxyadenosine, rat (Bennett et al 2016) and  
7  
8 mouse models (Zhou et al 2019) of DGUOK deficiency have not studied the impact of dGMP,  
9  
10 dAMP, or dGMP + dAMP treatment.  
11  
12  
13

14  
15 Currently, there are no curative therapies available for DGUOK deficiency (Viscomi and Zeviani  
16  
17 2017). Given that formation of a nucleoside monophosphate intermediate is rate-limiting in  
18  
19 nucleic acid synthesis, an emphasis in MDS therapeutic development has been placed on  
20  
21 nucleoside monophosphate prodrugs capable of bypassing defective nucleoside kinases.  
22  
23 Prodrugs, and ultimately ProTides, are compounds that, when metabolized, are broken down  
24  
25 into a pharmacologically active drug, or nucleotide. One such approach employs a  
26  
27 phosphoramidate masking group as the foundation of the ProTide nucleotide, providing a  
28  
29 functional handle with drug-like properties susceptible to intracellular, enzyme-mediated  
30  
31 activation to a nucleoside monophosphate (**Figure 1A**). Preclinical evaluation of ProTide  
32  
33 nucleotides is typically limited to *in vitro* models, as high esterase activity in mouse and rat  
34  
35 plasma rapidly degrade the ProTide prodrug moiety and precludes the use of *in vivo* rodent  
36  
37 models (Rudakova et al 2011; Bahar et al 2012).  
38  
39  
40  
41  
42  
43

44  
45 This study was designed to evaluate the utility of a novel ProTide nucleotide of dGMP, CERC-  
46  
47 913, in a primary hepatocyte culture model of DGUOK deficiency. DGUOK-deficient hepatocyte  
48  
49 cultures display significantly reduced mtDNA content that was restored in a dose-dependent  
50  
51 fashion upon treatment with CERC-913. Overall, our work further establishes the usefulness of  
52  
53 cell culture systems in understanding the pathogenesis of DGUOK deficiency, while also  
54  
55 illustrating the promise of ProTide prodrugs relative to unmodified nucleoside monophosphates  
56  
57 as a therapeutic approach to MDS.  
58

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7 **Materials and Methods**

8  
9 *Preclinical Characterization of CERC-913*

10 A battery of standard preclinical assays was performed to identify the most suitable dGMP  
11 ProTide for further study (see Supplementary Materials). A Caco-2 cell line permeability assay  
12 was performed to evaluate the likelihood of passive and transporter-mediated diffusion across  
13 cellular membranes. Plasma stability assays were performed to determine relative stability of  
14 test compounds under physiological conditions. HepG2 (ATCC, HB8065) cells were used to  
15 test viability and effects on mitochondrial membrane potential. The Mini-Ames assay and an in  
16 vitro micronucleus assay were used to assess the genotoxic potential of CERC-913.  
17  
18

19 Additionally, a pharmacokinetic study in dogs was used to determine plasma exposure and  
20 clearance of CERC-913 after oral and IV administration.  
21  
22

23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33 *Establishment of Primary Hepatocyte Cultures*

34 Primary hepatocytes were isolated from the livers of DGUOK KO and wild type (WT) rats  
35 (Bennett et al 2016) of either sex at ages ranging from 4.9 to 12.5 weeks (Shen et al 2012) (See  
36 Supplementary Materials). Cells were initially plated using Williams' complete medium, which  
37 was changed to HepatoZYME-SFM (Gibco, #1882882) after 1 hour of culture and changed  
38 daily. Cell viability was measured using Abcam MTT proliferation kit (Abcam, ab211091).  
39  
40  
41  
42  
43  
44  
45  
46  
47

48  
49 *Efficacy of CERC-913*

50 On the day following cell isolation, CERC-913 (Cerecor) was added to the growth medium of  
51 DGUOK KO primary hepatocytes at 50, 100, 200, 400, or 800  $\mu$ M, with dGMP was used as an  
52 agent previously shown to rescue mtDNA depletion *in vitro* (Bulst et al, 2019). mtDNA content  
53 was evaluated as previously described (Bennett et al 2016). Subsequent experiments focused  
54  
55  
56  
57  
58

59 on comparisons of CERC-913 and dGMP at doses of 200, 400, and 800  $\mu$ M and endpoints  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 included mtDNA content and western blot. Western blots were performed as previously  
5 described (Bennett et al 2016) and using mtCO1 antibody (Abcam, 1D6E1A8, 1:1000) as an  
6 indicator of mitochondrial protein expression. Quantification of protein levels normalized to  
7 SDHA (Cell Signaling, D6J9M, 1:1000) was performed with Image Lab Software (BIO-RAD).  
8  
9

10  
11  
12  
13  
14  
15 *Statistical Evaluation:* Data from all mtDNA experiments was transformed on a logarithmic  
16 scale. A ROUT analysis was performed on western blot data to identify potential outliers. The  
17 data from mtDNA and western blot experiments was evaluated using a one-way ANOVA with  
18 multiple comparisons. A two-way ANOVA analysis was used to evaluate mtDNA timecourse  
19 data.  
20  
21  
22  
23  
24  
25

## 26 27 28 **Results**

### 29 30 31 32 *Preclinical characterization of CERC-913*

33  
34  
35  
36  
37 An absorption, distribution, metabolism, and excretion screening campaign of several  
38 dGMP ProTides was performed, focusing on the Caco-2 cell line permeability and plasma  
39 stability as primary criteria to select a candidate for testing in DGUOK-deficient hepatocytes.  
40 The negative charge of nucleoside monophosphates at physiological pH decrease the likelihood  
41 of passive diffusion across cell membranes, while plasma phosphatases are capable of rapidly  
42 cleaving the phosphate group prior to reaching the desired site of action. The ProTide prodrug  
43 approach improves cell permeability and plasma stability by increasing lipophilicity and  
44 incorporating a non-hydrolyzable phosphate masking group. CERC-913 was selected  
45 as the lead compound based on desirable physicochemical properties, including increased  
46 permeability and stability relative to dGMP (**Figure 1B**).  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 CERC-913 was evaluated for *in vitro* toxicity by assessing cell viability and mitochondrial  
5 membrane potential in HepG2 cells. CERC-913 showed no impact on cell viability relative to  
6 staurosporine positive control and similarly showed no impact on mitochondrial membrane  
7 potential relative to FCCP positive control at the concentrations tested (1 to 3000 uM). Given  
8 CERC-913 is a nucleoside-based therapeutic designed as a substrate for DNA synthesis, an  
9 evaluation of any potential genotoxic effects was conducted. The results of Ames and *in*  
10 *vitro* micronucleus assays, which tests whether CERC-913 causes DNA mutations, were  
11 negative, demonstrating CERC-913 to be non-genotoxic.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

23  
24 Plasma pharmacokinetics (PK) of CERC-913 were assessed in beagle dogs to evaluate the *in*  
25 *vivo* absorption, distribution, metabolism and elimination of CERC-913. A single oral or  
26 intravenous dose was given to three animals. The oral half-life ( $T_{1/2}$ ) of CERC-913 in plasma  
27 was determined to be roughly 0.7 hours and the oral bioavailability (%F) was 77%. Sofosbuvir  
28 (Sovaldi<sup>®</sup>, Gilead), a revolutionary treatment for Hepatitis C Virus (HCV), was the first approved  
29 drug containing a variation of the ProTide phosphoramidate masking group (Sofia et al 2010;  
30 Slusarczyk et al 2018) and more recently anticancer ProTides have entered clinical trials  
31 (Slusarczyk et al 2014; Blagden et al 2018). CERC-913 contains a ProTide moiety similar  
32 to sofosbuvir and other marketed nucleotide prodrugs known to have liver-targeting properties  
33 (Sofia et al 2010; Furman et al 2011; Vernachio et al 2011; Murakami et al 2014). When  
34 comparing the plasma PK of single 50 mg/kg oral doses of CERC-913 and sofosbuvir in beagle  
35 dogs, CERC-913 displayed a slightly improved or comparable exposure profile on all  
36 parameters (**Figure 1C**).  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52

53  
54  
55 *mtDNA depletion in DGUOK KO primary hepatocytes*  
56  
57  
58

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 The impact of primary hepatocyte culture on mtDNA depletion was assessed to ensure that  
5  
6 DGUOK-derived primary hepatocytes displayed a useful degree of mtDNA depletion. Primary  
7  
8 hepatocyte cell cultures were isolated from livers of DGUOK KO and wild type (WT) rats  
9  
10 (Bennett et al 2016) of either sex as previously described (Shen et al 2012). The mtDNA  
11  
12 content from WT and DGUOK KO primary hepatocyte cultures was assessed daily to determine  
13  
14 whether mtDNA content was variable over time and to identify useful timepoints for treatment  
15  
16 studies. MtDNA content was assessed by RTqPCR (described in supplemental methods)  
17  
18 comparing mitochondrial specific primers relative to nuclear primers. As cell yields and viability  
19  
20 were variable between isolations from different animals (n = 3 animals per genotype in this  
21  
22 experiment), mtDNA copies were compared to age- and timepoint-matched cultures from WT  
23  
24 rats. Over the 8-day period of culture following primary hepatocyte isolation, DGUOK KO  
25  
26 primary hepatocyte cultures showed a consistent proportion of mtDNA depletion ranging from  
27  
28 7.1-10.6% of WT values during this period (p<0.0001, **Figure 2A**), similar to the 90% reduction  
29  
30 in mtDNA that was reported in liver tissue from this DGUOK KO rat colony (Bennett et al 2016).  
31  
32 WT cultures showed stable mtDNA copies for the first 4 days in culture, with a decrease in  
33  
34 mtDNA copies after day 4. This was accompanied by a subjective decrease in cellularity in  
35  
36 these WT cultures (**Figure 2B**) that suggests that the mtDNA decrease was due to cell loss.  
37  
38 Pilot cell cultures followed past 8 days showed poor viability, establishing that later timepoints  
39  
40 with this culture system were impractical for our purposes. Subsequent experiments were  
41  
42 performed with key timepoints including 4 and 8 days in culture to account for changes in cell  
43  
44 viability while also allowing the maximum duration of treatment to observe therapeutic effects.  
45  
46  
47  
48  
49  
50  
51  
52

#### 53 *Establishment of CERC-913 effective dose in primary hepatocyte cultures*

54  
55  
56

57  
58 Based on the demonstration of stable mtDNA depletion over 8 days in culture, dose escalation  
59  
60 experiments were performed with a focus on mtDNA recovery after 4 days in culture. A dose  
61  
62  
63  
64  
65

1  
2  
3  
4 escalation strategy incorporating 0  $\mu$ M, 50  $\mu$ M, 100  $\mu$ M, 200  $\mu$ M, 400  $\mu$ M, and 800  $\mu$ M CERC-  
5  
6 913 per well was used with media containing CERC-913 changed daily starting at day 1  
7  
8 following isolation. When compared to the relative mtDNA copy number DGUOK KO  
9  
10 hepatocytes receiving no CERC-913 (355.6 mtDNA copies), 50  $\mu$ M CERC-913 did not  
11  
12 significantly increase mtDNA copy number (668.3 mtDNA copies,  $p = 0.13$ ), while 100-800  $\mu$ M  
13  
14 CERC-913 significantly increased relative mtDNA copy number levels (**Figure 3A**). This  
15  
16 increase was dose-dependent with an increase at 100  $\mu$ M (772.4 mtDNA copies,  $p < 0.05$ ) and  
17  
18 an increase which plateaued at 200, 400, and 800  $\mu$ M (1042, 1033, and 1048 mtDNA copies,  
19  
20 respectively,  $p < 0.01$ ). Based on these findings, additional studies were performed focusing on  
21  
22 doses of 0  $\mu$ M, 200  $\mu$ M, 400  $\mu$ M, and 800  $\mu$ M CERC-913.  
23  
24  
25  
26  
27  
28

#### 29 *Assessment of CERC-913 efficacy in comparison to dGMP*

30  
31  
32  
33

34 A focused experiment was performed to establish whether CERC-913 provided greater mtDNA  
35  
36 recovery than dGMP, previously dGMP + dAMP had been shown to improve mtDNA content in  
37  
38 DGUOK-deficient cells (Taanman et al 2003; Saada 2008; Bulst et al 2009; Bulst et al 2012). In  
39  
40 our hands, dGMP + dAMP did not significantly improve mtDNA recovery (1.4 fold increase)  
41  
42 beyond what was observed using dGMP alone (1.7 fold increase; **Supplementary Figure 1**)  
43  
44 (Camara et al., 2012. Equivalent doses (0  $\mu$ M, 200  $\mu$ M, 400  $\mu$ M, and 800  $\mu$ M) were tested for  
45  
46 both CERC-913 and dGMP and mtDNA content was assessed after 4 and 8 days in culture  
47  
48 (**Figure 3B and 3C**). In comparison to the mtDNA copy numbers observed in KO control  
49  
50 hepatocytes (413.6 and 335.1 mtDNA copies for four and eight days, respectively), dGMP did  
51  
52 not significantly increase relative mtDNA copy numbers at any dose at 4 days (200, 400, 800  
53  
54  $\mu$ M; 398.5, 443.4, and 586.1 mtDNA copies, respectively) and only significantly increased  
55  
56 relative mtDNA copy numbers at the 800  $\mu$ M dose at eight days (200, 400, 800  $\mu$ M; 424.4,  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 511.3, and 663.7 mtDNA copies, respectively,  $p < 0.05$ ). CERC-913 significantly increased  
5  
6 relative mtDNA copy numbers at 200, 400 and 800  $\mu\text{M}$  at 4 days (1018.7, 927.9, and 975.5  
7  
8 mtDNA copies, respectively,  $p < 0.05$ ) and 8 days (1109.2, 1202.0, and 1294.8 mtDNA copies,  
9  
10 respectively,  $p < 0.0001$ ) when compared to KO control hepatocytes after 4 and 8 days in culture.  
11  
12 For all treatment conditions and timepoints, the relative mtDNA copy numbers remained  
13  
14 significantly different in comparison to untreated wild type (WT) hepatocytes at 4 and 8 days  
15  
16 (4181.7 and 2215.7 mtDNA copies, respectively,  $p < 0.0001$ ). When comparing mtDNA content  
17  
18 after treatment between CERC-913 and dGMP conditions, CERC-913 treated cells showed  
19  
20 significantly higher mtDNA content at 200  $\mu\text{M}$  at 4 and 8 days in comparison to dGMP treated  
21  
22 cells and a similar difference was observed at 8 days when comparing the 400  $\mu\text{M}$  dose of  
23  
24 CERC-913 versus dGMP ( $p < 0.05$ ). There was no significant difference in mtDNA content when  
25  
26 comparing CERC-913 and dGMP treated cells at 800  $\mu\text{M}$  doses at either timepoint.  
27  
28  
29  
30  
31  
32  
33

#### 34 *Assessment of additional efficacy endpoints with CERC-913 treatment*

35  
36  
37

38 The impact of CERC-913 treatment on protein expression and cell viability was assessed to  
39  
40 determine whether additional efficacy endpoints beyond mtDNA content are improved over 8  
41  
42 days of treatment in this cell culture system. Cell viability at 4 and 8 days in culture was  
43  
44 assessed using an MTT assay in cultures treated with 0, 200, 400 and 800  $\mu\text{M}$  of CERC-913.  
45  
46 As noted in our earlier experiments, cell viability was more consistent after 4 days in culture,  
47  
48 with nonsignificant trends toward fewer cells in all conditions at 8 days. Treatment with CERC-  
49  
50 913 did not significantly affect cell viability at any dose (**Figure 4A**). With respect to protein  
51  
52 expression, western blots were used to assess the expression of subunit 1 of cytochrome c  
53  
54 oxidase, the mitochondrial electron complex IV (mtCO1), using protein isolates from six different  
55  
56 treatment experiments. Expression levels of key proteins were highly variable between different  
57  
58

59  
60  
61  
62  
63  
64  
65



1  
2  
3  
4 primary cell culture isolations (each derived from different animals), suggesting that a  
5  
6 demonstration of statistically significant improvements in protein expression using this culture  
7  
8 system will likely be challenging. While the level of mtCO1 protein was consistently decreased  
9  
10 in untreated DGUOK cells in comparison to WT (**Figure 4B**,  $p < 0.01$ ), extensive variation in the  
11  
12 overall amount of protein expression in WT and DGUOK KO cells complicated the analysis of  
13  
14 treatment-related increases in mtCO1. This variation between isolations was also observed in  
15  
16 proteins commonly used as loading controls. For instance, the WT culture from our second  
17  
18 isolation in this experiment showed very high mtCO1 protein levels but essentially undetectable  
19  
20 GAPDH and SDHA protein levels.  
21  
22  
23  
24  
25  
26  
27

## 28 **Discussion**

29  
30  
31  
32  
33 DGUOK deficiency is an MDS resulting in devastating morbidity, primarily manifesting in the  
34  
35 liver, along with death for which there is no currently available therapeutic option. Prior work  
36  
37 has supported the notion of bypassing DGUOK by supplementing cells with nucleoside  
38  
39 monophosphates, but delivery and uptake of nucleoside monophosphates to tissues *in vivo* in  
40  
41 rodent models is limited. This study focused on the design of a liver-specific model of DGUOK  
42  
43 deficiency to evaluate the efficacy of a novel ProTide prodrug of dGMP. CERC-913 was  
44  
45 designed to resist dephosphorylation and passively diffuse across cell membranes to a greater  
46  
47 extent than dGMP. To circumvent the poor rodent plasma stability of ProTides (McGuigan et al  
48  
49 2010; Vernachio et al 2011; Bahar et al 2012; Siegel et al 2017), a primary hepatocyte cell  
50  
51 culture model was developed using liver tissue from DGUOK KO rats (Bennett et al 2016). The  
52  
53 model was evaluated for its ability to recapitulate mtDNA depletion phenotype observed in  
54  
55 DGUOK-deficient patients and assess the efficacy of CERC-913 relative to dGMP.  
56  
57  
58

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 DGUOK deficiency has been studied *in vitro* using patient-derived fibroblast and myoblast  
5  
6 cultures, and *in vivo* using transgenic modeling in mice and rats. Cellular models have been  
7  
8 essential in establishing how *DGUOK* mutations result in mtDNA depletion. Studies using  
9  
10 DGUOK-mutant cell cultures have also established that treatment of cells with deoxyguanosine  
11  
12 and deoxyadenosine, or with dGMP and dAMP, is capable of partially correcting mtDNA content  
13  
14 (Taanman et al 2003; Saada 2008; Bulst et al 2009; Bulst et al 2012). A recent study using  
15  
16 DGUOK-mutant, iPSC-derived hepatocytes found that mitochondrial respiratory phenotypes  
17  
18 were improved by treatment with nicotinamide adenine dinucleotide (NAD) (Jing et al 2018).  
19  
20 With respect to *in vivo* models, our group has previously reported a *DGUOK* KO rat model with  
21  
22 a mild phenotype despite an approximately 90% reduction in mtDNA copy number in liver  
23  
24 tissues (Bennett et al 2016), that has since been used to evaluate nicotinamide riboside as a  
25  
26 means of increasing NAD<sup>+</sup> levels, which significantly improved the function of several  
27  
28 mitochondrial electron transport chain (ETC) complexes I, III, IV, and V (Jing et al 2018). The  
29  
30 use of this rat model in interventional studies, however, is complicated by the almost complete  
31  
32 lack of behavioral or pathological abnormalities in the animals. Additionally, a mouse model of  
33  
34 DGUOK deficiency has recently been described that develops a more severe disease  
35  
36 phenotype, including weight loss, lipofuscin accumulation in the liver, and an approximately 99%  
37  
38 reduction in mtDNA in the liver, with smaller relative decreases in other organs (Zhou et al  
39  
40 2019). Overall, each of these model systems has reinforced the impact of DGUOK on mtDNA  
41  
42 content while highlighting the difficulty of recapitulating the severe clinical phenotypes observed  
43  
44 in humans at equivalent levels of mtDNA deficiency. The DGUOK KO rat model provided liver  
45  
46 tissue for primary hepatocyte culture in this study, allowing an assessment of mtDNA depletion,  
47  
48 cell viability and protein expression.  
49  
50  
51  
52  
53  
54  
55

56  
57 Previous studies of bypass therapy in DGUOK deficiency demonstrate that nucleoside  
58

59  
60 supplementation can be an effective pharmacological approach to DGUOK deficiency *in vitro*  
61  
62  
63  
64  
65

1  
2  
3  
4 (Buchaklian et al 2012; Camara et al 2014). However, the cell types employed in prior studies  
5  
6 may not provide an ideal context for evaluating kinase bypass, since active nuclear DNA  
7  
8 replication during S phase could enable importation of cytosolic nucleoside metabolites for  
9  
10 mtDNA synthesis and compensate for mutant DGUOK. Furthermore, improved intracellular  
11  
12 delivery of dGMP is required to make kinase bypass more practical. Nucleoside  
13  
14 monophosphates, such as dGMP, are negatively charged, making them highly polar and  
15  
16 incapable of passively diffusing across cellular membranes. Plasma phosphatases rapidly  
17  
18 degrade nucleoside monophosphates prior to reaching the desired site of action. ProTide  
19  
20 nucleotides, including CERC-913, display enhanced stability in human plasma and improved  
21  
22 membrane permeability relative to nucleoside monophosphates. Such properties allow ProTides  
23  
24 to cross cellular membranes intact, after which a carefully orchestrated intracellular activation  
25  
26 process reveals the active monophosphate metabolite (Furman et al 2011; Vernachio et al  
27  
28 2011; Serpi et al 2013; Murakami et al 2014; Maize et al 2017).  
29  
30  
31  
32  
33

34  
35 In this study, we compared CERC-913 to dGMP with respect to their ability to improve mtDNA  
36  
37 content in primary DGUOK KO hepatocyte cultures. CERC-913 performed significantly better  
38  
39 than equivalent doses of dGMP, which had much less of an impact on mtDNA content in  
40  
41 hepatocytes than previously observed in patient-derived fibroblasts. The hepatocyte model  
42  
43 provides additional insight into the context-dependency of mtDNA depletion. The ability to  
44  
45 import cytosolic nucleosides into mitochondria requires active DNA replication during S-phase  
46  
47 and can compensate for insufficient de novo mtDNA synthesis. Our model further demonstrates  
48  
49 that quiescent cell-types, unable to enter S-phase, are particularly vulnerable to mutations in  
50  
51 mitochondrial nucleoside kinases, as evidenced by the severe (>90%) mtDNA depletion in  
52  
53 DGUOK KO hepatocytes relative to WT hepatocytes. We also attempted to establish additional  
54  
55 efficacy endpoints related to functional recovery of DGUOK KO hepatocytes, including cell  
56  
57  
58

59  
60 viability and expression of mtCO1. Unfortunately, variation between replicates (including WT  
61  
62  
63  
64  
65

1  
2  
3  
4 control samples) limited the usefulness of these studies, and so no clear-cut therapeutic effects  
5  
6 could be demonstrated using these assays. This variation was likely in part due to the limitations  
7  
8 in experimental time-course due to short-term hepatocyte viability in cell culture.  
9

10  
11  
12  
13 The ProTide nucleotide exemplifies a validated approach to kinase bypass that has enabled the  
14  
15 development and approval of multiple drug candidates. A single, daily 400 mg oral dose of the  
16  
17 ProTide sofosbuvir establishes liver concentrations of roughly ~100  $\mu\text{M}$  in HCV patients at  
18  
19 steady-state (Babusis et al 2018). In our model, CERC-913 induced significant rescue of mtDNA  
20  
21 depletion at effective concentrations as low as 100  $\mu\text{M}$  and PK experiments in dog  
22  
23 demonstrated an improved plasma exposure profile relative to sofosbuvir. The data generated  
24  
25 in our hepatocyte model help toward understanding a therapeutic threshold to further develop  
26  
27 pharmacokinetic-pharmacodynamic (PKPD) relationships for translation to DGUOK-deficient  
28  
29 patients.  
30  
31  
32

33  
34  
35 In addition to severe liver dysfunction, DGUOK-deficient patients can also experience serious  
36  
37 and life-threatening neurological symptoms that often result in early mortality, even following  
38  
39 successful liver transplantation. Another critical feature of developing a substrate replacement  
40  
41 therapy for DGUOK deficiency is determining the ability of dGMP ProTides to reach the CNS  
42  
43 and provide the opportunity to rescue or impede neurological deterioration. Further nonclinical  
44  
45 evaluation of CERC-913 as a therapy for DGUOK deficiency, including its ability to cross the  
46  
47 blood-brain barrier in appreciable amounts, is currently underway.  
48  
49  
50  
51  
52

53  
54  
55 **FIGURES**  
56  
57  
58

59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4 **Figure 1: Properties of CERC-913.** (A) ProTide prodrug activation pathway for CERC-913 to  
5 yield dGMP. (B) Physicochemical properties of CERC-913 in comparison to dGMP. <sup>a</sup>A-B/B-A  
6 with efflux inhibitor, <sup>b</sup>recovery <2%, <sup>c</sup>% remaining @ 2 hours in rat, dog and human, ND = Not  
7 Detectable at any time point later than 5 minutes post-incubation. (C) PK parameters of CERC-  
8 913 in dogs after a single 50 mg/kg oral dose. CERC-913 compares favorably to sofosbuvir, the  
9 first-ever approved ProTide nucleotide as an oral therapy with liver-targeting properties. <sup>d</sup>First  
10 dose, <sup>e</sup>Steady-state, <sup>f</sup>Estimated (no IV dosing arm included).

11  
12  
13 **Figure 2: Primary cell culture of WT and DGUOK KO hepatocytes.** (A) mtDNA content in  
14 WT vs. DGUOK KO primary hepatocytes over 8 days in culture. Statistical analysis was  
15 performed by running an analysis of variance on Log10 transformed relative mtDNA copy  
16 number values. Data are represented as mean ± SEM (B) Relative cellularity of WT and  
17 DGUOK KO primary hepatocytes after 4 and 8 days in culture. \*\*\*\*p<0.0001.

18  
19  
20  
21  
22  
23 **Figure 3: Effects of CERC-913 treatment on mtDNA content in primary hepatocyte**  
24 **cultures.** (A) Impact of escalating CERC-913 dose on mtDNA content in DGUOK KO  
25 hepatocyte cultures after 4 days in culture. (B) Comparison of treatment-related mtDNA  
26 increases between CERC-913 and dGMP after 4 days in culture. (C) Comparison of treatment-  
27 related mtDNA increases between CERC-913 and dGMP after 8 days in culture. Data are  
28 stated as relative mtDNA copy number, but statistical analysis was performed by analysis of  
29 variance (ANOVA) on Log10 transformed mtDNA relative copy number values. Data are  
30 represented as mean ± SEM. Symbols identify statistical significance with different  
31 comparisons: \*Compared to WT control, #Compared to KO control, †Compared to CERC  
32 200, and ‡Compared to CERC 400. The number of symbols denotes level of statistical  
33 significance (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001, \*\*\*\*p<0.0001).

1  
2  
3  
4  
5  
6  
7 **Figure 4: Effects of CERC-913 treatment on other cellular endpoints in primary**

8 **hepatocyte cultures.** (A) Impact of effective CERC-913 doses on cell viability in DGUOK KO  
9 hepatocyte cultures. (B) Impact of effective CERC-913 doses on mitochondrial protein  
10 expression in DGUOK KO hepatocyte cultures isolated in 6 different sets of animals, with cells  
11 collected at 4 and 8 days in culture. mtCO1 is used as an example of a mtDNA-encoded  
12 protein that is likely to be affected by differences in mtDNA copy number. GAPDH and SDHA  
13 are nuclear-encoded proteins meant to serve as loading controls. Note that the WT cell culture  
14 from isolation 2 shows highly abnormal protein expression patterns with respect to all of these  
15 proteins at 4 and 8 days. The values from this specimen are not included in the graphs or  
16 statistical analysis shown due to these aberrations, and so the "WT Control" condition in the  
17 graph represents n=5 whereas all other graphed conditions represent n=6 isolations. Data are  
18 represented as mean  $\pm$  SEM. \*\*p<0.01, \*\*\*p<0.001.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

## References


- Babuis D, Curry MP, Kirby B, et al (2018) Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus. *Antimicrob Agents Chemother* 62.
- Bahar FG, Ohura K, Ogihara T, Imai T (2012) Species difference of esterase expression and hydrolase activity in plasma. *J Pharm Sci* 101: 3979-3988.
- Bennett B, Helbling D, Meng H, et al (2016) Potentially diagnostic electron paramagnetic resonance spectra elucidate the underlying mechanism of mitochondrial dysfunction in the deoxyguanosine kinase deficient rat model of a genetic mitochondrial DNA depletion syndrome. *Free Radic Biol Med* 92: 141-151.
- Blagden SP, Rizzuto I, Suppiah P, et al (2018) Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study. *Br J Cancer* 119: 815-822.
- Buchaklian AH, Helbling D, Ware SM, Dimmock DP (2012) Recessive deoxyguanosine kinase deficiency causes juvenile onset mitochondrial myopathy. *Mol Genet Metab* 107: 92-94.
- Bulst S, Abicht A, Holinski-Feder E, et al (2009) In vitro supplementation with dAMP/dGMP leads to partial restoration of mtDNA levels in mitochondrial depletion syndromes. *Hum Mol Genet* 18: 1590-1599.
- Bulst S, Holinski-Feder E, Payne B, et al (2012) In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion. *Mol Genet Metab* 107: 95-103.
- Camara Y, Gonzalez-Vioque E, Scarpelli M, et al (2014) Administration of deoxyribonucleosides or inhibition of their catabolism as a pharmacological approach for mitochondrial DNA depletion syndrome. *Hum Mol Genet* 23: 2459-2467.
- Furman PA, Murakami E, Niu C, et al (2011) Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. *Antiviral Res* 91: 120-132.

- 1  
2  
3  
4 Gower WR, Jr., Carr MC, Ives DH (1979) Deoxyguanosine kinase. Distinct molecular forms in  
5  
6 mitochondria and cytosol. *J Biol Chem* 254: 2180-2183.  
7  
8  
9 Jing R, Corbett JL, Cai J, et al (2018) A Screen Using iPSC-Derived Hepatocytes Reveals  
10  
11 NAD(+) as a Potential Treatment for mtDNA Depletion Syndrome. *Cell Rep* 25: 1469-  
12  
13 1484 e1465.  
14  
15 Maize KM, Shah R, Strom A, et al (2017) A Crystal Structure Based Guide to the Design of  
16  
17 Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) Activated ProTides. *Mol*  
18  
19 *Pharm* 14: 3987-3997.  
20  
21  
22 McGuigan C, Gilles A, Madela K, et al (2010) Phosphoramidate ProTides of 2'-C-  
23  
24 methylguanosine as highly potent inhibitors of hepatitis C virus. Study of their in vitro and  
25  
26 in vivo properties. *J Med Chem* 53: 4949-4957.  
27  
28  
29 Murakami E, Wang T, Babusis D, et al (2014) Metabolism and pharmacokinetics of the anti-  
30  
31 hepatitis C virus nucleotide prodrug GS-6620. *Antimicrob Agents Chemother* 58: 1943-  
32  
33 1951.  
34  
35  
36 Rudakova EV, Boltneva NP, Makhaeva GF (2011) Comparative analysis of esterase activities of  
37  
38 human, mouse, and rat blood. *Bull Exp Biol Med* 152: 73-75.  
39  
40  
41 Saada A (2008) Mitochondrial deoxyribonucleotide pools in deoxyguanosine kinase deficiency.  
42  
43 *Mol Genet Metab* 95: 169-173.  
44  
45  
46 Salviati L, Sacconi S, Mancuso M, et al (2002) Mitochondrial DNA depletion and dGK gene  
47  
48 mutations. *Ann Neurol* 52: 311-317.  
49  
50  
51 Serpi M, Madela K, Pertusati F, Slusarczyk M (2013) Synthesis of phosphoramidate prodrugs:  
52  
53 ProTide approach. *Curr Protoc Nucleic Acid Chem* Chapter 15: Unit15 15.  
54  
55  
56 Sezer T, Ozcay F, Balci O, Alehan F (2015) Novel deoxyguanosine kinase gene mutations in  
57  
58 the hepatocerebral form of mitochondrial DNA depletion syndrome. *J Child Neurol* 30:  
124-128.



- 1  
2  
3  
4 Shen L, Hillebrand A, Wang DQ, Liu M (2012) Isolation and primary culture of rat hepatic cells. *J*  
5  
6 *Vis Exp.*  
7  
8  
9 Siegel D, Hui HC, Doerffler E, et al (2017) Discovery and Synthesis of a Phosphoramidate  
10  
11 Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the  
12  
13 Treatment of Ebola and Emerging Viruses. *J Med Chem* 60: 1648-1661.  
14  
15 Slusarczyk M, Lopez MH, Balzarini J, et al (2014) Application of ProTide technology to  
16  
17 gemcitabine: a successful approach to overcome the key cancer resistance mechanisms  
18  
19 leads to a new agent (NUC-1031) in clinical development. *J Med Chem* 57: 1531-1542.  
20  
21  
22 Slusarczyk M, Serpi M, Pertusati F (2018) Phosphoramidates and phosphonamidates  
23  
24 (ProTides) with antiviral activity. *Antivir Chem Chemother* 26: 2040206618775243.  
25  
26  
27 Sofia MJ, Bao D, Chang W, et al (2010) Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-  
28  
29 C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. *J*  
30  
31 *Med Chem* 53: 7202-7218.  
32  
33  
34 Taanman JW, Muddle JR, Muntau AC (2003) Mitochondrial DNA depletion can be prevented by  
35  
36 dGMP and dAMP supplementation in a resting culture of deoxyguanosine kinase-  
37  
38 deficient fibroblasts. *Hum Mol Genet* 12: 1839-1845.  
39  
40  
41 Vernachio JH, Bleiman B, Bryant KD, et al (2011) INX-08189, a phosphoramidate prodrug of 6-  
42  
43 O-methyl-2'-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with  
44  
45 excellent pharmacokinetic and pharmacodynamic properties. *Antimicrob Agents*  
46  
47 *Chemother* 55: 1843-1851.  
48  
49  
50 Viscomi C, Zeviani M (2017) MtDNA-maintenance defects: syndromes and genes. *J Inherit*  
51  
52 *Metab Dis* 40: 587-599.  
53  
54  
55 Zhou X, Curbo S, Zhao Q, Krishnan S, Kuiper R, Karlsson A (2019) Severe mtDNA depletion  
56  
57 and dependency on catabolic lipid metabolism in DGUOK knockout mice. *Hum Mol*  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65






**B**



Physicochemical Property	CERC-913	dGMP
Caco-2 P., (x 10 <sup>-6</sup> )	0.812.1	0.3/0.5b
Plasma Stability (r/d/h)c	0 / 95 / 99	NO


**C**


PK Parameter	CERC-913d	Sofosbuvir•
C <sub>mu</sub> (Jg/mL)	7.3	6.2
T <sub>1/2</sub> (h)	1.3	0.5
AUC <sub>0-∞</sub> (μg"hlml)	12.5	6.9
T <sub>1/2</sub> (h)	0.7	0.6
Bioavail:ability (%F)	77%	-10% <sub>1</sub>


















[Click here to access/download](#)

**Other material**

**[Cerc supplementary materials for resubmission.docx](#)**







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Beatka.pdf**







Click here to access/download

Conflict of Interest Disclosure Form (signed and scanned)

coi\_disclosure\_Crutcher.pdf







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Dimmock.pdf**






Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Helbling.pdf**







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Lawlor.pdf**







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Meng.pdf**







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Pertusati.pdf**









Click here to access/download



**Conflict of Interest Disclosure Form (signed and scanned)**


**coi\_disclosure\_Pileggi.pdf**





Click here to access/download  
**Conflict of Interest Disclosure Form (signed and  
scanned)**  
coi\_disclosure\_Prom.pdf







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Serpi.pdf**







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Slick.pdf**







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Sutton.pdf**







Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Thomas.pdf**





Click here to access/download

**Conflict of Interest Disclosure Form (signed and scanned)**

**coi\_disclosure\_Vanden Avond.pdf**

